Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam continuous sedation dose-effect and tourniquet ischemia-reperfusion study in lower extremity orthopedic surgery
ChiCTR2000035274Phase 4Recruiting
- Sponsor
- Shaoyang Central Hospital
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam and midazolam in procedural sedation and analgesia (PSA) (5 arms), sponsored by Shaoyang Central Hospital. Primary endpoints: Bispectral index, Modified Observer's Assessment of Alertness/Sedation and 6 more. Started Aug 2020; status: recruiting.
02
Drugs
remimazolammidazolam
03
Conditions
procedural sedation and analgesia (PSA)
Beyond the preview
Go deeper on ChiCTR2000035274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035274.